• Global Clinical Research & Health Data Analytics Company
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • Webinars
  • MMS Blog
  • Careers
  • Contact Us
MMS Holdings
GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS

GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS

by Don McLean | May 5, 2020 | News

GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a...
Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope

Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope

by curtis@digitalliance.com | Jun 27, 2017 | Blog

Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope by Ben Kaspar, July 27, 2017 In the United States, the number of patients with Alzheimer’s disease is projected to increase from the current prevalence of around 5.5...

Recent Posts

  • Modernizing the Functional Service Provider (FSP) Relationship: Innovations to bring value beyond “Global and Scalable”
  • EY Announces Dr. Uma Sharma of MMS Holdings as an Entrepreneur Of The Year® 2020 Michigan and Northwest Ohio Award Finalist
  • MichBio Invites MMS Founder and Chief Scientific Officer Dr. Uma Sharma to Join Board of Directors
  • How Zero Contact GXP Audits Ensure Compliance While Protecting Auditors and Auditees during the Global Pandemic
  • FDA Orphan Drug Designation Applications Whitepaper

Tags

ALZ awareness Alzheimers biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance COVID-19 CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission opioids pharma pharmacovigilance PhUSE Policy 0070 quality control rare disease real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering